^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:ADC2122 (HER2-targeted antibody-drug conjugate, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors

    Excerpt:
    ...Having HER2-positive disease, i.e. HER2 positive by in situ hybridization on previously collected tumor tissue and/or immunohistochemistry of 3+....
    Trial ID:
    ZV0203-001CN
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    438P - Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors

    Published date:
    10/16/2023
    Excerpt:
    Among 11 pts evaluated, 2 pts achieved a best tumor response of PR; 5 pts had SD; 1 pt had Non-CR/Non-PD per RECIST v1.1….ZV0203 has a manageable safety profile with preliminary antitumor activity in heavily pretreated pts with HER2+ cancer.